B
3.18
-0.04 (-1.24%)
| Previous Close | 3.22 |
| Open | 3.31 |
| Volume | 64,856 |
| Avg. Volume (3M) | 236,995 |
| Market Cap | 114,003,000 |
| Price / Sales | 109.70 |
| Price / Book | 0.510 |
| 52 Weeks Range | |
| Earnings Date | 20 Mar 2025 |
| Operating Margin (TTM) | -1,133.43% |
| Diluted EPS (TTM) | -1.98 |
| Total Debt/Equity (MRQ) | 3.29% |
| Current Ratio (MRQ) | 13.68 |
| Operating Cash Flow (TTM) | -53.21 M |
| Levered Free Cash Flow (TTM) | -34.85 M |
| Return on Assets (TTM) | -19.54% |
| Return on Equity (TTM) | -30.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | BioAge Labs, Inc. | Bearish | - |
AIStockmoo Score
0.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 66.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redpoint Management, Llc | 31 Dec 2024 | 383,255 |
| 52 Weeks Range | ||
| Median | 5.00 (57.23%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 24 Mar 2025 | 5.00 (57.23%) | Hold | 4.54 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jun 2025 | Announcement | BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates |
| 29 May 2025 | Announcement | BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic |
| 27 May 2025 | Announcement | BioAge Labs to Present at Upcoming Investor Conferences |
| 06 May 2025 | Announcement | BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates |
| 20 Mar 2025 | Announcement | BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 |
| 17 Mar 2025 | Announcement | BioArctic receives Orphan Drug Designation for exidavnemab the US |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |